Lack of effect of nizatidine-induced elevation of gastric pH on the oral bioavailability of dapsone in healthy volunteers

Pharmacotherapy. 2002 Nov;22(11):1420-5. doi: 10.1592/phco.22.16.1420.33698.

Abstract

Study objective: To investigate the effect of histamine2 (H2)-receptor antagonist-induced elevation of gastric pH on oral bioavailability of a single dose of dapsone 100 mg.

Design: Prospective, randomized, crossover, open-label, single-dose pharmacokinetic study.

Setting: Teaching hospital.

Patients: Sixteen men were enrolled in the study; data from 11 subjects were evaluable.

Interventions: Participants received two treatments separated by at least 14 days. Treatment A consisted of a single dose of dapsone 100 mg. Treatment B consisted of a single dose of dapsone 100 mg plus two doses of oral nizatidine 300 mg administered 3-4 hours apart to maintain gastric pH above 6.0. Plasma samples collected before and up to 120 hours after dapsone administration were analyzed for dapsone and monoacetyldapsone (MADDS) by high-performance liquid chromatography. Pharmacokinetic parameters were determined by noncompartmental analysis.

Measurements and main results: Gastric pH in the first 6 hours after dapsone administration was above 6.0 for a mean +/- SD of 1.1% +/- 2.9% of the time in the absence of nizatidine and 69.5% +/- 18.0% of the time during nizatidine therapy. The geometric mean dapsone maximum plasma concentration (Cmax) declined by 13% (p<0.01), and median time to Cmax occurred 2 hours later (p<0.01) with nizatidine coadministration compared with dapsone alone. Inclusion of the 90% confidence interval for the mean Cmax ratio within the equivalence interval of 0.8-1.25 demonstrated the lack of clinical significance for this modest decrease in Cmax. Neither the area under the dapsone plasma concentration-time curve from zero to infinity nor the elimination half-life of dapsone were significantly altered by nizatidine. No clinically significant changes were observed in the pharmacokinetics of MADDS with regard to coadministration of nizatidine.

Conclusion: Elevation of gastric pH by H2-receptor antagonists, such as nizatidine, does not result in clinically important changes in the rate or extent of oral dapsone absorption.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Adolescent
  • Adult
  • Analysis of Variance
  • Area Under Curve
  • Biological Availability
  • Cross-Over Studies
  • Dapsone / administration & dosage
  • Dapsone / blood
  • Dapsone / pharmacokinetics*
  • Drug Interactions / physiology
  • Gastric Acid / metabolism*
  • Humans
  • Hydrogen-Ion Concentration / drug effects
  • Linear Models
  • Male
  • Nizatidine / blood
  • Nizatidine / pharmacokinetics*
  • Nizatidine / pharmacology
  • Prospective Studies
  • Statistics, Nonparametric

Substances

  • Dapsone
  • Nizatidine